JP2020514386A - ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置 - Google Patents

ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置 Download PDF

Info

Publication number
JP2020514386A
JP2020514386A JP2019552040A JP2019552040A JP2020514386A JP 2020514386 A JP2020514386 A JP 2020514386A JP 2019552040 A JP2019552040 A JP 2019552040A JP 2019552040 A JP2019552040 A JP 2019552040A JP 2020514386 A JP2020514386 A JP 2020514386A
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
patients
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019552040A
Other languages
English (en)
Japanese (ja)
Inventor
ジェフリー・ミン
モーシャ・イー・ジルバースタイン
ローイェー・カリミ・アンデレシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority claimed from PCT/EP2018/057310 external-priority patent/WO2018172465A1/en
Publication of JP2020514386A publication Critical patent/JP2020514386A/ja
Priority to JP2023003470A priority Critical patent/JP2023040241A/ja
Priority to JP2025031035A priority patent/JP2025087764A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2019552040A 2017-03-22 2018-03-22 ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置 Pending JP2020514386A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023003470A JP2023040241A (ja) 2017-03-22 2023-01-13 ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
JP2025031035A JP2025087764A (ja) 2017-03-22 2025-02-28 ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762475173P 2017-03-22 2017-03-22
US62/475,173 2017-03-22
EP17306079 2017-08-18
EP17306079.9 2017-08-18
PCT/EP2018/057310 WO2018172465A1 (en) 2017-03-22 2018-03-22 Treatment of lupus using humanized anti-cxcr5 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023003470A Division JP2023040241A (ja) 2017-03-22 2023-01-13 ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置

Publications (1)

Publication Number Publication Date
JP2020514386A true JP2020514386A (ja) 2020-05-21

Family

ID=61827719

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019552040A Pending JP2020514386A (ja) 2017-03-22 2018-03-22 ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
JP2023003470A Pending JP2023040241A (ja) 2017-03-22 2023-01-13 ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
JP2025031035A Pending JP2025087764A (ja) 2017-03-22 2025-02-28 ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023003470A Pending JP2023040241A (ja) 2017-03-22 2023-01-13 ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
JP2025031035A Pending JP2025087764A (ja) 2017-03-22 2025-02-28 ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置

Country Status (7)

Country Link
US (1) US20240207397A1 (https=)
EP (1) EP3601344A1 (https=)
JP (3) JP2020514386A (https=)
KR (2) KR20190131068A (https=)
CN (1) CN110662767A (https=)
AU (1) AU2018238540B2 (https=)
IL (2) IL318907A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023010483A1 (en) * 2021-08-05 2023-02-09 Hifibio (Hk) Limited Anti-human cxcr5 antibody and uses thereof
WO2021216505A1 (en) * 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cxcl13 gene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537636A (ja) * 2007-08-29 2010-12-09 サノフィ−アベンティス ヒト化抗ｃｘｃｒ５抗体、その誘導体及びそれらの使用
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2016028573A1 (en) * 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr5

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537636A (ja) * 2007-08-29 2010-12-09 サノフィ−アベンティス ヒト化抗ｃｘｃｒ５抗体、その誘導体及びそれらの使用
JP2015096075A (ja) * 2007-08-29 2015-05-21 サノフイ ヒト化抗ｃｘｃｒ５抗体、その誘導体及びそれらの使用
WO2012010582A1 (en) * 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2016028573A1 (en) * 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr5

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"PHARMACODYNAMICS ASSESSMENT STUDY AFTER SINGLE SUBCUTANEOUS DOSE OF SAR113244 以下備考", CLINICALTRIALS.GOV, JPN5020004277, 3 June 2016 (2016-06-03), ISSN: 0004731579 *

Also Published As

Publication number Publication date
IL269419A (en) 2019-11-28
KR20250052493A (ko) 2025-04-18
JP2025087764A (ja) 2025-06-10
IL318907A (en) 2025-04-01
EP3601344A1 (en) 2020-02-05
JP2023040241A (ja) 2023-03-22
AU2018238540A1 (en) 2019-11-07
CN110662767A (zh) 2020-01-07
KR20190131068A (ko) 2019-11-25
US20240207397A1 (en) 2024-06-27
AU2018238540B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
JP5926162B2 (ja) 炎症傷害の処置および評価
EP3237447B1 (en) Anti-csf1r antibodies for treating pvns
KR20150018533A (ko) 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
JP2025087764A (ja) ヒト化抗ｃｘｃｒ５抗体を使用するループスの処置
JP2008544960A5 (https=)
KR20150119155A (ko) Pan-ELR+ CXC 케모카인 항체
JP7727633B2 (ja) イヌインターロイキン－４受容体αに対する抗体
JP2017078075A (ja) 対象の選択および治療
US20250276059A1 (en) Therapeutic methods and agents for the treatment of myocardial infarction
US20210077619A1 (en) Treatment of lupus using humanized anti-cxcr5 antibodies
US20160002326A1 (en) Compositions and methods for treating rheumatoid arthritis
WO2016118921A1 (en) Compositions and methods for treating psoriatic arthritis
KR20210060582A (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
RU2840044C1 (ru) Антитела к собачьему альфа-рецептору интерлейкина-4
RU2838943C1 (ru) Антитела к собачьему альфа-рецептору интерлейкина-4
EA040840B1 (ru) Антитела против csf1r для лечения pvns

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220913